ANI Pharmaceuticals
ANIP
171 hedge funds and large institutions have $401M invested in ANI Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 69 increasing their positions, 33 reducing their positions, and 13 closing their positions.
254% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 13
109% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 33
59% more capital inflows, than outflows
Capital inflows: $75M | Capital outflows: $47.1M
24% more funds holding
Funds holding: 138 → 171 (+33)
3.67% more ownership
Funds ownership: 48.47% → 52.14% (+3.7%)
2% more call options, than puts
Call options by funds: $11.9M | Put options by funds: $11.7M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Glenmede Trust
Philadelphia,
Pennsylvania
|
+$8.35M |
| 2 |
Renaissance Technologies
New York
|
+$7.32M |
| 3 |
Castleark Management
Chicago,
Illinois
|
+$6.29M |
| 4 |
Bank of New York Mellon
New York
|
+$4.61M |
| 5 |
BlackRock Fund Advisors
San Francisco,
California
|
+$3.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$10.3M |
| 2 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
-$9.07M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$3.62M |
| 4 |
Perceptive Advisors
New York
|
-$3.48M |
| 5 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
-$2.65M |
ANIP Hedge Fund Activity: Q3 2016 in Review
171 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q3 2016, worth a combined $401M — up 28% from $313M a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new ANIP positions and 13 closed out — a net gain of 33 holders — while 69 added to existing stakes and 33 trimmed.
The largest buyer was Glenmede Trust, opening a new position worth an estimated $8.35M. The largest seller was Consonance Capital Management, cutting an estimated $10.3M.
- 171 institutional investors held ANI Pharmaceuticals (ANIP) as of Q3 2016, up from 138 in Q2 2016.
- Funds reported $401M of ANI Pharmaceuticals stock for Q3 2016, up 28% quarter-over-quarter.
- 46 funds opened new ANI Pharmaceuticals positions in Q3 2016 and 13 closed out, a net change of +33 holders.
- The largest ANI Pharmaceuticals buyer in Q3 2016 was Glenmede Trust, an estimated $8.35M added.
- The largest ANI Pharmaceuticals seller in Q3 2016 was Consonance Capital Management, an estimated $10.3M sold.
Based on aggregated 13F filings for Q3 2016.